BioSpace News Archive

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces that the United States Patent and Trademark Office (USPTO) has issued a first notice of allowance for a patent application covering OSE-279, an anti-PD1 monoclonal antibody, and its use in cancer treatment.

Exactech announced today the new product innovations and Active Intelligence® technologies to be showcased at the company’s educational exhibit, Booth #3014, at the American Academy of Orthopaedic Surgeons (AAOS) 2022 Annual Meeting, March 22-26, in Chicago, Il.

MaaT Pharma announced the implementation of a liquidity agreement with Kepler Cheuvreux to enhance the liquidity of the MaaT Pharma shares admitted to trading on Euronext Paris.

Research published today in Nature Chemical Biology reveals new opportunities for using small molecule drugs to target KRAS, the most commonly mutated protein in cancer.

Padagis today announced the FDA approval and launch of an AB-rated generic version of Tobradex® Ophthalmic Suspension.

Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESARTM RNA delivery platform, today announced it has signed a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to evaluate the potential of its vaccine for COVID-19.

Top levels of nutrients and optimal amalgamation of growth factors make it an ideal growth supplement for cell cultures.

Increase in the incidence of lung-related syndromes and rise in geriatric population, in the last few years has driven the growth of the lung injury market in more than one way.

As per a report circulated by WHO, in 2010, more than five hundred million people were in the age group of sixty-five years and above, and this count is anticipated to hit almost two billion by the year 2050, which is around sixteen percent of the global population.

Over the last decade, there’s been a steep incline in the incidence of structural heart diseases, which has given way to growing adoption of prosthetic valves across the world.